Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clonidine/oxybutynin - Orient Pharma

Drug Profile

Clonidine/oxybutynin - Orient Pharma

Alternative Names: DL 06001; OP-014; SMT D001

Latest Information Update: 05 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DanioLabs
  • Developer Orient Pharma
  • Class Alkynes; Analgesics; Antiglaucomas; Antimigraines; Antispasmodics; Behavioural disorder therapies; Carbocyclic acids; Centrally-acting antihypertensives; Chlorobenzenes; Cyclohexanes; Diethylamines; Esters; Imidazolines; Mandelic acids; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Cholinergic receptor antagonists; Imidazoline receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Sialorrhoea

Most Recent Events

  • 05 Apr 2021 Discontinued - Preregistration for Sialorrhoea in South Korea, New Zealand, India, Malaysia, Hong Kong, Japan, Philippines, China, Canada, European Union, USA (PO) (NDR Batch 18)
  • 25 Jan 2019 Clonidine/oxybutynin is not yet available for Sialorrhoea in Australia and Singapore (PO)
  • 25 Jan 2019 No recent reports of development identified after preregistration for Sialorrhoea in USA, European Union, Canada, China, China, Japan, Philippines, Hong Kong, Malaysia, India, New Zealand, South Korea (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top